查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1668040

疱疹性咽峡炎治疗市场 - 全球产业规模、份额、趋势、机会和预测，按治疗、病毒、最终用户、地区和竞争细分，2020-2030 年预测

Herpangina Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By Virus, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 184 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球疱疹性咽峡炎治疗市场价值为 18.9 亿美元，预计到 2030 年将达到 28.6 亿美元，复合年增长率为 7.14%。 由于病毒感染的盛行率不断上升，尤其是在儿童中，全球疱疹性咽峡炎治疗市场正在稳步增长。疱疹性咽峡炎是由柯萨奇病毒 A 等肠病毒引起的，会导致咽喉疼痛性溃疡和发烧，需要透过止痛药、退烧药和补水疗法进行症状治疗。疱疹性咽峡炎的发病率上升，加上父母对病毒感染的认知不断提高，推动了对有效治疗方案的需求。医疗保健提供者强调早期诊断和适当的支持性护理，从而促进市场扩张。非处方止痛药的供应和儿科医疗设施的进步进一步支持了市场的成长，确保及时管理受影响个体的症状。

市场概况
预测期 2026-2030
2024 年市场规模 18.9 亿美元
2030 年市场规模 28.6 亿美元
2025-2030 年复合年增长率 7.14％
成长最快的领域 柯萨奇病毒A
最大的市场 北美洲

远距医疗和数位医疗解决方案的日益普及，大大提高了儿科咨询的机会，使得能够及时诊断和治疗疱疹性咽峡炎病例。抗病毒疗法的持续研究和有针对性的治疗方法的开发有望彻底改变市场。人们对预防性医疗保健的日益关注，包括肠病毒相关感染的疫苗接种研究，提供了一个潜在的成长途径。製药公司积极投入儿科药物配方，确保为年轻患者提供安全有效的治疗方案。医疗基础设施的扩张和医疗支出的上升正在提高医疗服务的可近性，尤其是在新兴经济体。

欠发达地区对疱疹性咽峡炎症状和治疗方案的认识有限仍然是一个重大挑战。由于缺乏针对疱疹性咽峡炎的特定抗病毒药物，导致人们只能依赖对症治疗，从而限制了治疗进展。对自我药疗和不当使用止痛药的担忧进一步阻碍了有效的疾病管理。儿科药物审批的严格监管要求增加了新型治疗方案的开发和商业化的复杂性。市场也面临与季节性疫情相关的挑战，这造成需求波动，使得医疗保健系统难以保持一致的准备。应对这些挑战需要医疗保健组织、政府和製药公司之间的共同努力，以提高意识、研究资金和治疗的可及性。

主要市场驱动因素

疱疹性咽峡炎盛行率高

主要市场挑战

诊断工具不足

主要市场趋势

抗病毒疗法的进展

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：全球疱疹性咽峡炎治疗市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依治疗（局部麻醉剂、布洛芬或对乙酰氨基酚、其他治疗）
    • 依病毒分类（柯萨奇病毒 A、柯萨奇病毒 B、肠病毒 71、埃可病毒）
    • 按最终使用者（医院、家庭护理、专科诊所、其他）
    • 按地区
    • 按公司分类（2024）
  • 市场地图
    • 按治疗
    • 病毒
    • 按最终用户
    • 按地区

第 5 章：亚太地区疱疹性咽峡炎治疗市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 按治疗
    • 病毒
    • 按最终用户
    • 按国家
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 澳洲
    • 日本
    • 韩国

第 6 章：欧洲疱疹性咽峡炎治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 7 章：北美疱疹性咽峡炎治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 墨西哥
    • 加拿大

第 8 章：南美洲疱疹性咽峡炎治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 阿根廷
    • 哥伦比亚

第 9 章：中东和非洲疱疹性咽峡炎治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 沙乌地阿拉伯
    • 阿联酋

第 10 章：市场动态

  • 驱动程式
  • 挑战

第 11 章：市场趋势与发展

  • 最新动态
  • 产品发布
  • 合併与收购

第 12 章：全球疱疹性咽峡炎治疗市场：SWOT 分析

第 13 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 14 章：竞争格局

  • Gilead Sciences Inc
  • Johnson and Johnsons
  • Merck & Co. Inc
  • Pfizer Inc.
  • AbbVie Inc.
  • Vertex Pharmaceuticals Incorporated
  • Sanofi SA
  • Novartis AG
  • Mitsubishi Tanabe Pharma Corporation
  • F. Hoffmann-La Roche Ltd

第 15 章：策略建议

第16章 调査会社について・免责事项

简介目录
Product Code: 18977

Global Herpangina Treatment Market was valued at USD 1.89 Billion in 2024 and is expected to reach USD 2.86 Billion in the forecast period with a CAGR of 7.14% through 2030. The Global Herpangina Treatment Market is witnessing steady growth due to the increasing prevalence of viral infections, particularly among children. Herpangina, caused by enteroviruses such as Coxsackievirus A, leads to painful ulcers in the throat and fever, requiring symptomatic management through pain relievers, antipyretics, and hydration therapy. The rising incidence of herpangina, coupled with growing parental awareness about viral infections, is fueling demand for effective treatment options. Healthcare providers are emphasizing early diagnosis and appropriate supportive care, contributing to market expansion. The availability of over-the-counter pain relief medications and advancements in pediatric healthcare facilities further support market growth, ensuring timely management of symptoms in affected individuals.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.89 Billion
Market Size 2030USD 2.86 Billion
CAGR 2025-20307.14%
Fastest Growing SegmentCoxsackie Virus A
Largest MarketNorth America

The increasing adoption of telemedicine and digital healthcare solutions has significantly enhanced access to pediatric consultations, allowing for prompt diagnosis and management of herpangina cases. Continuous research in antiviral therapies and the development of targeted treatment approaches are expected to revolutionize the market. The rising focus on preventive healthcare, including vaccination research for enterovirus-related infections, presents a potential growth avenue. Pharmaceutical companies are actively investing in pediatric drug formulations, ensuring safe and effective treatment solutions tailored to young patients. The expansion of healthcare infrastructure and rising healthcare expenditure are driving higher accessibility to medical services, particularly in emerging economies.

Limited awareness about herpangina symptoms and treatment options in underdeveloped regions remains a major challenge. The absence of specific antiviral drugs for herpangina leads to reliance on symptomatic care, limiting treatment advancements. Concerns regarding self-medication and improper use of pain relief medications further hinder effective disease management. Stringent regulatory requirements for pediatric drug approvals add complexities to the development and commercialization of novel treatment solutions. The market also faces challenges related to seasonal outbreaks, which create fluctuations in demand, making it difficult for healthcare systems to maintain consistent preparedness. Addressing these challenges requires collaborative efforts among healthcare organizations, governments, and pharmaceutical companies to improve awareness, research funding, and treatment accessibility.

Key Market Drivers

High Prevalence of Herpangina

The high prevalence of herpangina is a compelling driver behind the robust growth of the Global Herpangina Treatment Market. Herpangina, a viral infection primarily affecting children, is characterized by painful throat sores, fever, and discomfort, making effective treatment imperative. The contagious nature of this illness ensures a consistent and sizable patient pool seeking medical attention, thereby fostering a constant demand for treatment options.

Children, especially those in school and daycare settings, are particularly susceptible to herpangina due to its ease of transmission through close contact. As a result, healthcare providers often encounter cases of herpangina, further underscoring the importance of developing effective treatments. The global prevalence of herpangina ensures that pharmaceutical companies and medical device manufacturers remain highly motivated to invest in research, development, and innovation in this niche healthcare sector.

Additionally, medical device manufacturers contribute to the market by developing diagnostic tools and equipment that aid healthcare professionals in the rapid and accurate identification of herpangina-causing viruses. These tools facilitate early intervention and prompt treatment, particularly in crowded and high-risk environments such as schools and daycare centers.

While specific recent statistics on herpangina prevalence are limited, data on related enteroviral infections provide insight into the disease's impact. For instance, during a 1998 outbreak in Taiwan, a total of 129,106 cases of hand, foot, and mouth disease (HFMD) and herpangina were reported. This highlights the substantial burden such viral infections can impose on healthcare systems. Given the cyclical nature of enteroviral outbreaks, similar patterns may be observed in subsequent years, underscoring the ongoing need for effective herpangina treatments. In summary, the persistent and widespread occurrence of herpangina, especially among children in communal settings, drives continuous demand for effective treatments. This demand propels pharmaceutical and medical device companies to innovate and develop targeted therapies and diagnostic tools, thereby contributing to the growth of the Global Herpangina Treatment Market.

Key Market Challenges

Inadequate Diagnostic Tools

The Global Herpangina Treatment Market, dedicated to addressing the medical needs of individuals suffering from the viral infection herpangina, faces a significant hurdle in the form of inadequate diagnostic tools. Herpangina is a contagious illness primarily affecting children and is characterized by painful throat sores, fever, and discomfort. Timely and accurate diagnosis is essential for effective treatment and containment of the disease, but the current diagnostic landscape presents challenges that hinder the market's progress.

One of the primary challenges in the herpangina treatment market is the absence of rapid and reliable diagnostic tools for identifying the viruses responsible for herpangina, notably the Coxsackievirus. Unlike some other infectious diseases with readily available diagnostic tests, herpangina lacks specific point-of-care diagnostic options. As a result, healthcare professionals often face delays in confirming a herpangina diagnosis, leading to potential misdiagnosis or the spread of the virus in high-risk environments like schools and daycare centers.

The limited availability of diagnostic tools can exacerbate the challenges associated with herpangina treatment. Without a rapid and definitive diagnosis, healthcare providers may resort to empiric treatments that focus on symptom management rather than targeting the underlying viral infection. This approach not only increases the risk of incorrect treatments but also delays the initiation of antiviral therapies, if applicable.

Moreover, inadequate diagnostic tools can hinder the ability to isolate infected individuals promptly, which is crucial in containing outbreaks, especially in settings where herpangina can easily spread among children. Without efficient diagnostic tests, identifying and isolating cases becomes a manual and time-consuming process, potentially allowing the virus to spread further.

Key Market Trends

Advancements in Antiviral Therapies

Advancements in antiviral therapies are playing a pivotal role in boosting the Global Herpangina Treatment Market. Herpangina, a viral infection primarily affecting children and characterized by painful throat sores, fever, and general discomfort, has long presented a challenge to healthcare providers due to its contagious nature and the lack of specific treatment options. However, recent strides in antiviral therapies are transforming the landscape of herpangina treatment.

Pharmaceutical companies are dedicating significant resources to research and develop novel antiviral drugs tailored specifically for herpangina-causing viruses, notably the Coxsackievirus. These advancements aim to address the root cause of herpangina by inhibiting the replication and spread of the virus within the body. By targeting the viral infection directly, these antiviral drugs not only alleviate the symptoms but also reduce the duration of the illness.

One of the significant advantages of these advanced antiviral therapies is their potential to combat drug-resistant strains of the virus. Over time, viruses like Coxsackievirus can adapt and become resistant to existing medications, rendering them less effective. The development of new antiviral compounds with diverse mechanisms of action helps mitigate the risk of resistance, ensuring that patients receive treatment that remains efficacious.

Additionally, these advancements in antiviral therapies contribute to enhancing the overall quality of care for individuals affected by herpangina. By shortening the duration of the illness and reducing the severity of symptoms, patients experience quicker relief and a more comfortable recovery process. This not only improves their well-being but also reduces the burden on healthcare systems by minimizing hospitalizations and outpatient visits.

Furthermore, these innovative antiviral therapies provide healthcare professionals with more effective tools for managing herpangina cases. They can confidently prescribe targeted antiviral medications that address the underlying viral infection, offering patients a more tailored and comprehensive treatment approach.

Key Market Players

  • Gilead Sciences Inc
  • Johnson and Johnsons
  • Merck & Co. Inc
  • Pfizer Inc.
  • AbbVie Inc.
  • Vertex Pharmaceuticals Incorporated
  • Sanofi S.A
  • Novartis AG
  • Mitsubishi Tanabe Pharma Corporation
  • F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Herpangina Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Herpangina Treatment Market, By Treatment:

  • Topical Anesthetics
  • Ibuprofen or Acetaminophen
  • Other Treatments

Herpangina Treatment Market, By Virus:

  • Coxsackie Virus A
  • Coxsackie Virus B
  • Enterovirus 71
  • Echovirus

Herpangina Treatment Market, By End User:

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Herpangina Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Herpangina Treatment Market.

Available Customizations:

Global Herpangina Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Herpangina Treatment Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Treatment (Topical Anesthetics, Ibuprofen or Acetaminophen, Other Treatments)
    • 4.2.2. By Virus (Coxsackie Virus A, Coxsackie Virus B, Enterovirus 71, Echovirus)
    • 4.2.3. By End User (Hospitals, Homecare, Specialty Clinics, Others)
    • 4.2.4. By Region
    • 4.2.5. By Company (2024)
  • 4.3. Market Map
    • 4.3.1. By Treatment
    • 4.3.2. By Virus
    • 4.3.3. By End User
    • 4.3.4. By Region

5. Asia Pacific Herpangina Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment
    • 5.2.2. By Virus
    • 5.2.3. By End User
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Herpangina Treatment Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Treatment
        • 5.3.1.2.2. By Virus
        • 5.3.1.2.3. By End User
    • 5.3.2. India Herpangina Treatment Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Treatment
        • 5.3.2.2.2. By Virus
        • 5.3.2.2.3. By End User
    • 5.3.3. Australia Herpangina Treatment Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Treatment
        • 5.3.3.2.2. By Virus
        • 5.3.3.2.3. By End User
    • 5.3.4. Japan Herpangina Treatment Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Treatment
        • 5.3.4.2.2. By Virus
        • 5.3.4.2.3. By End User
    • 5.3.5. South Korea Herpangina Treatment Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Treatment
        • 5.3.5.2.2. By Virus
        • 5.3.5.2.3. By End User

6. Europe Herpangina Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Virus
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Herpangina Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By Virus
        • 6.3.1.2.3. By End User
    • 6.3.2. Germany Herpangina Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By Virus
        • 6.3.2.2.3. By End User
    • 6.3.3. Spain Herpangina Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By Virus
        • 6.3.3.2.3. By End User
    • 6.3.4. Italy Herpangina Treatment Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Treatment
        • 6.3.4.2.2. By Virus
        • 6.3.4.2.3. By End User
    • 6.3.5. United Kingdom Herpangina Treatment Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Treatment
        • 6.3.5.2.2. By Virus
        • 6.3.5.2.3. By End User

7. North America Herpangina Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By Virus
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Herpangina Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By Virus
        • 7.3.1.2.3. By End User
    • 7.3.2. Mexico Herpangina Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By Virus
        • 7.3.2.2.3. By End User
    • 7.3.3. Canada Herpangina Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By Virus
        • 7.3.3.2.3. By End User

8. South America Herpangina Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Virus
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Herpangina Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By Virus
        • 8.3.1.2.3. By End User
    • 8.3.2. Argentina Herpangina Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By Virus
        • 8.3.2.2.3. By End User
    • 8.3.3. Colombia Herpangina Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By Virus
        • 8.3.3.2.3. By End User

9. Middle East and Africa Herpangina Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By Virus
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Herpangina Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By Virus
        • 9.3.1.2.3. By End User
    • 9.3.2. Saudi Arabia Herpangina Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By Virus
        • 9.3.2.2.3. By End User
    • 9.3.3. UAE Herpangina Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By Virus
        • 9.3.3.2.3. By End User

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Herpangina Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Gilead Sciences Inc
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Johnson and Johnsons
  • 14.3. Merck & Co. Inc
  • 14.4. Pfizer Inc.
  • 14.5. AbbVie Inc.
  • 14.6. Vertex Pharmaceuticals Incorporated
  • 14.7. Sanofi S.A
  • 14.8. Novartis AG
  • 14.9. Mitsubishi Tanabe Pharma Corporation
  • 14.10. F. Hoffmann-La Roche Ltd

15. Strategic Recommendations

16. About Us & Disclaimer